Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hecht R et al. - New approaches are needed to generate more resources, make funding more stable and flexible, and further engage the expertise of the pharmaceutical industry. Several new financing mechanisms have been launched recently, and others are being proposed. This paper summarizes some of the most promising new ideas and offers a framework for evaluating them.

Related Articles

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09    Relevance Score: 89%

Faiz Kermani The rise of in silico R&D
Pharmaceutical Technology, 10/14/09    Relevance Score: 84%

Cephalon, Inc. to Webcast R&D Day
Cephalon, 11/05/09    Relevance Score: 80%

Cerner Enters R&D Pact with University
HealthDataManagement, 10/06/09    Relevance Score: 80%

Novartis delivers strong new product momentum and operational performance in first nine months of 2009
Novartis, 10/23/09    Relevance Score: 77%

Today in Economics of Medicine...keeping you current

California to receive federal matching funds for electronic health record incentives program
Centers for Medicare & Medicaid Services Press, 12/18/09

Understanding the Economic Impact of a Pandemic
AMN Healthcare, 12/17/09

HHS Gets Advice on Incentive Definitions
HealthDataManagement, 12/16/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address